The useful accident in Jeff Elkins’s career happened at a clinical trial at Stanford. Elkins was working for World Medical Manufacturing on an early aortic endograft. Thomas Fogarty, the surgeon-inventor, was there with what Elkins cheerfully called a “competing” device. Competition became acquaintance. The companies behind both technologies were later acquired by Medtronic, and Elkins moved to the Bay Area to help integrate and scale the product. Years afterward, Fogarty would give him two pieces of direction that narrowed the next part of his career. But the first lesson arrived without being announced: in medical devices, rivals, mentors, colleagues, buyers and future partners keep reappearing around the same small table.
Elkins has now spent more than 30 years at that table. His official biography runs through Cordis, World Medical, Medtronic, FlowMedica, Aptus EndoSystems, Veniti and InterVene. The titles shift from research and development to operations, chief technology officer, business-unit leader, chief operating officer and chief executive. Read quickly, it resembles a collection of senior jobs and acquisitions. Read slowly, and a more useful idea emerges: he kept adding another way to understand how a technical choice travels through a company.
01 / The education
When the hardware was still becoming a category
Elkins graduated from the University of Massachusetts Amherst with a mechanical engineering degree. His first job was at Cordis on the East Coast, when coronary balloon procedures were new and coronary stents were still a concept. It was an unusually good classroom for an engineer: the category had not yet settled into familiar language, established workflows or obvious product assumptions.
World Medical brought him to early aortic endografts. Medtronic brought the integration problem. Building a device is one kind of work; making it survive a larger organization, broader production and wider use is another. Elkins later served as vice president and business-unit manager for Medtronic’s endovascular division. The engineer was learning that scale has its own tolerances.
02 / Range
Four jobs hiding inside one title
A 2003 FDA filing for a FlowMedica infusion system lists Elkins as vice president of R&D and COO. Those two labels beside one name are a miniature of his career. One faces the product. The other faces everything required to make the product repeatable. Elkins was also a FlowMedica founder and later its CEO. In 2009, AngioDynamics acquired key assets of the company, including its Benephit product line.
At Aptus EndoSystems, he moved through operations, COO and CEO responsibilities. In 2012, when James Reinstein became chief executive, Elkins stayed as senior vice president and COO and remained on the board. Three years later, Medtronic acquired Aptus assets in a transaction valued at approximately $110 million. Remaining useful after the title changes is a less celebrated management skill than winning the title. It may also be the more revealing one.
Then came Veniti. As president and CEO, Elkins led a company building a stent designed around the particular mechanical demands of veins. Boston Scientific already owned 25 percent when it agreed in 2018 to acquire the rest for $108 million upfront and as much as $52 million in contingent payments. In the announcement, Elkins focused on access: the technology could reach more physicians through the larger company. It was an operator’s reading of an exit. The transaction mattered because distribution could extend the work.
“If you build a culture of focusing on the patient, the business success will follow.”Jeff Elkins
03 / The note from Fogarty
Two assignments, checked off years later
The Stanford competitor became a long-running connection. Elkins helped lay out and set up the Fogarty Institute lab while the space was being built. About a decade before Elkins recounted the story in 2019, Fogarty advised him to concentrate on the emerging venous field and to work on either a venous stent or a venous valve. Elkins later described his time leading Veniti and joining InterVene as checking both items off the list.
The anecdote sounds tidy only in retrospect. In practice, it required staying close to one technical neighborhood while repeatedly changing seats. The thread was not a single company. It was a problem space, a network of experienced people and a growing store of pattern recognition. Careers are often described as ladders because ladders are easy to draw. Elkins’s looks more like a workshop wall: each tool has a different purpose, and fluency comes from knowing which one the moment requires.
04 / The operating system
A founder’s playbook without the theater
When asked for the secret behind companies that find acquirers, Elkins did not begin with deal mechanics. He began with culture, integrity and immersion. His advice forms a compact operating system for technical startups.
Earn the reputation before the reference call
Integrity, in his account, compounds across teams, investors and buyers. A reputation arrives at the meeting before the founder does.
Know the room behind the pitch room
Visit physicians, watch procedures, read the literature, understand the data and respect the field’s pioneers. Cursory knowledge rarely earns a second conversation.
Learn the other half of the company
Engineers need the business and business leaders need the engineering. Important decisions are impolite about departmental boundaries.
Hire multi-position players
Early teams need people willing to take on more than one facet of the work. Range protects momentum when the next problem refuses to match the org chart.
Temper passion with realism
Elkins values passion because it builds confidence, but he pairs it with a clear view of the challenge. Energy needs an instrument panel.
His point about liking the people around you is similarly practical. Small teams can work at an intensity that makes chemistry part of the infrastructure. Excellence is hard to maintain if everyone dreads the room. Elkins’s preference for versatile colleagues is also self-descriptive. Across his own career, technical depth did not give way to business judgment. It fed it.
The operator’s loop
05 / Consequences
Where assumptions turn into cash burn
One sentence in Elkins’s advice deserves to be pinned above more startup desks. He spends time preventing potential problems, avoiding assumptions and thinking through what happens if a decision is wrong. In a regulated hardware company, the consequences connect quickly. A design shortcut can become a manufacturing issue. A manufacturing issue can become a schedule slip. A schedule slip can become extra financing. The diagram from technical choice to company risk is drawn in permanent ink.
This is why his career range matters. The CTO can recognize the mechanism. The operator can recognize the process. The CEO can recognize the cash and credibility attached to both. Elkins’s public philosophy is not cautious in the sense of standing still. It is cautious in the older engineering sense: understand the loads before asking the structure to carry them.
“There is no substitute for passion.”Jeff Elkins
06 / The current chapter
From a two-item note to a cleared system
Elkins joined InterVene as COO in 2018 and became CEO in 2020. The Redwood City company came out of the Stanford Biodesign ecosystem and had been a company-in-residence at the Fogarty Institute. The loop was almost comically complete: a UMass engineer meets Fogarty at a Stanford trial, helps prepare Fogarty’s lab, follows his advice into venous technology, then leads a company shaped by the same institution.
The recent record has the measured cadence of device work. In October 2024, InterVene raised $13 million in a round led by Treo Ventures and RiverVest Venture Partners. The stated plan covered final development of its Recana catheter system, clinical cases, regulatory submission and preparation for commercialization. In July 2025, the company announced its first procedure with the system at University Hospital Galway in Ireland. In October, the FDA cleared Recana through the 510(k) pathway.
Elkins joins InterVene as chief operating officer.
He becomes chief executive officer and a director.
InterVene closes a $13 million Series A financing.
The company announces the first Recana procedure.
The FDA grants 510(k) clearance to the Recana system.
There is a temptation to make the acquisition the climax of every startup story. Elkins has enough of them for an impressive final paragraph. Yet his own advice keeps moving attention upstream, toward the culture before the deal, the fieldwork before the pitch and the assumption before the mistake. Those are the places where an operator still has leverage.
His career also makes a quiet case for staying with a hard domain. The job titles can change. The company names can disappear into larger ones. What remains is accumulated judgment: how a product behaves, how a team works, how a regulator reads, how a buyer listens and how one decision alters the choices that follow. Thirty years later, Elkins is still close to the small tools and the large consequences. That proximity appears to be the point.